Vericel Q3 2026 Earnings Date & Estimates

Vericel (NASDAQ:VCEL) is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and specialty biologic products for the treatment of severe medical conditions. The company’s products are designed to support tissue repair and regeneration, with an emphasis on orthopedic and burn-care applications.

Vericel’s primary product is MACI, an autologous cellularized scaffold used to repair full-thickness cartilage defects in the knee. The therapy is made from a patient’s own cartilage cells, which are expanded and seeded onto a collagen membrane before implantation. Vericel also markets Epicel, a cultured epidermal autograft used for patients with deep dermal or full-thickness burns, including cases involving extensive skin loss.

In addition, Vericel commercializes NexoBrid in North America. NexoBrid is an enzymatic debridement treatment intended to remove eschar from deep partial-thickness and full-thickness thermal burns. Vericel’s products are primarily used in the United States through relationships with orthopedic surgeons, burn centers and other specialized healthcare providers. The company is headquartered in Cambridge, Massachusetts.